Last reviewed · How we verify
NCT01704742
Prospective Study of Lymphoproliferative Diseases
trial in Non-Hodgkin's Lymphoma. Withdrawn.
Quick facts
| Lead sponsor | West Virginia University |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Sites | 2 locations across Kenya, United States |
Conditions studied
- Non-Hodgkin's Lymphoma — all drugs for Non-Hodgkin's Lymphoma →
- Hodgkin's Lymphoma — all drugs for Hodgkin's Lymphoma →
Sponsor
West Virginia University
Who can join
Eligibility, any sex, with Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will help researchers learn more about non-Hodgkin's lymphoma and Hodgkin's lymphoma and how it is treated in Kenya. Researchers want to see if having certain viruses like Epstein Barr Virus (EBV), Human Immunodeficiency Virus (HIV), and Kaposi's Sarcoma Herpes Virus (KSHV) affects lymphoma. Patients in Kenya who agree to be in this study will let the resesarchers look at their medical record, follow their normal cancer care, and have blood drawn to look at different proteins and viruses. Researchers would also like to look at part of the original tumor that was taken out of each patient. Some of these samples will be stored at Kenyatta National Hospital and research will be done on them later. This study does not involve any change in treatment, but only allows the study team to follow how a patient in Kenya with lymphoma is treated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT01704742
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Hodgkin's Lymphoma
Currently open trials in the same condition.
- NCT07202052 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) · Phase 2, PHASE3 · recruiting
- NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
- NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
- NCT05884333 — Cord Blood Transplant in Adults With Blood Cancers · Phase 2 · recruiting
- NCT04532203 — A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Maligna · EARLY_PHASE1 · recruiting
Other West Virginia University trials
Trials by the same sponsor.
- NCT06686914 — The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex · Phase 1 · recruiting
- NCT06791850 — Sustaining Home Heart Failure Palliative Care in Rural Appalachia · NA · recruiting
- NCT05705999 — Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study · NA · recruiting
- NCT05353244 — Effects of PrTMS on Performance · NA · withdrawn
- NCT06612788 — Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01704742 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by West Virginia University
- Last refreshed: 8 November 2016
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01704742.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing